- Home
- AIFU vs CANF Comparison
AIFU vs CANF Comparison
Compare AIFU & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIFU
- CANF
- Stock Information
- Founded
- AIFU 1998
- CANF 1994
- Country
- AIFU China
- CANF Israel
- Employees
- AIFU N/A
- CANF N/A
- Industry
- AIFU
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- AIFU
- CANF Health Care
- Exchange
- AIFU NYSE
- CANF Nasdaq
- Market Cap
- AIFU 7.2M
- CANF 7.9M
- IPO Year
- AIFU 2007
- CANF N/A
- Fundamental
- Price
- AIFU $0.12
- CANF $1.13
- Analyst Decision
- AIFU
- CANF Strong Buy
- Analyst Count
- AIFU 0
- CANF 2
- Target Price
- AIFU N/A
- CANF $14.00
- AVG Volume (30 Days)
- AIFU 652.3K
- CANF 423.1K
- Earning Date
- AIFU 05-06-2025
- CANF 05-06-2025
- Dividend Yield
- AIFU N/A
- CANF N/A
- EPS Growth
- AIFU N/A
- CANF N/A
- EPS
- AIFU 1.15
- CANF N/A
- Revenue
- AIFU $247,815,758.00
- CANF $674,000.00
- Revenue This Year
- AIFU N/A
- CANF $461.72
- Revenue Next Year
- AIFU $11.81
- CANF N/A
- P/E Ratio
- AIFU $0.11
- CANF N/A
- Revenue Growth
- AIFU N/A
- CANF N/A
- 52 Week Low
- AIFU $0.12
- CANF $1.22
- 52 Week High
- AIFU $3.84
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- AIFU N/A
- CANF 35.40
- Support Level
- AIFU N/A
- CANF $1.14
- Resistance Level
- AIFU N/A
- CANF $1.27
- Average True Range (ATR)
- AIFU 0.00
- CANF 0.12
- MACD
- AIFU 0.00
- CANF -0.02
- Stochastic Oscillator
- AIFU 0.00
- CANF 0.00
About AIFU FANHUA INC SPON ADS EACH REPR 20 ORD SHS
AIFU Inc is an independent financial services provider in China. It offer end-to-end business solutions spanning compliance, technology, products, services, operations, capital flow, and professional training. It connects customers with insurance protection, retirement planning, health management, asset management, and family governance services.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).